Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: Recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

Cardiovascular Diabetology

Volumn 16, Issue 1, 2017, Pages

  Schernthaner, Guntram ^a   Lehmann, Roger ^b   Prázný, Martin ^c   Czupryniak, Leszek ^d   Ducena, Kristine ^e   Fasching, Peter ^f   Janež, Andrej ^g   Karasik, Avraham ^h   Kempler, Peter ⁱ   Martinka, Emil ^j   Shestakova, Marina V ^k   Duvnjak, Lea Smirčić ^l   Tankova, Tsvetalina ^m  

^a Rudolfstitung Hospital   (Austria)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c CHARLES UNIVERSITY   (Czech Republic)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e UNIVERSITY OF LATVIA   (Latvia)

^f WILHELMINEN HOSPITAL   (Austria)

^g UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ SEMMELWEIS UNIVERSITY   (Hungary)

^j National Institute of Endocrinology and Diabetology   (Slovakia)

^k ENDOCRINOLOGY RESEARCH CENTRE   (Russian Federation)

^l UNIVERSITY OF ZAGREB   (Croatia)

^m MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

more..

Author keywords

Anti glycaemic drugs; Cardiovascular disease; Renal disease; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; CANAGLIFLOZIN; DULAGLUTIDE; EMPAGLIFLOZIN; EMPAGLIFLOZIN PLUS METFORMIN; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; INSULIN DEGLUDEC; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; ANTIDIABETIC AGENT;

ALGORITHM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSENSUS; CREATININE BLOOD LEVEL; DISEASE ASSESSMENT; DRUG COMBINATION; DRUG EFFICACY; EASTERN EUROPE; GLYCEMIC CONTROL; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT EDUCATION; PATIENT MONITORING; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PROTOCOL COMPLIANCE; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; EUROPE; EXPERT WITNESS; PROCEDURES; STANDARDS; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; EUROPE; EUROPE, EASTERN; EXPERT TESTIMONY; HUMANS; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 85031918717     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-017-0622-7     Document Type: Review

References (55)

1. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
2. Rao Kondapally Seshasai S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-41.
3. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32:187-92.
4. Johansen OE. Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World J Diabetes. 2015;6:1092-6.
5. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-71.
6. Chen X, Yang L, Zhai SD. Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies. Chin Med J. 2012;125:4301-6.
7. Florez H, Reaven PD, Bahn G, Moritz T, Warren S, Marks J, Reda D, Duckworth W, Abraira C, Hayward R, et al. Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial. Diabetes Obes Metab. 2015;17:949-55.
8. CMPH. Guideline on Clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Use CfMPfH, editor. London; 2012.
9. FDA. Guidance for industry. FDA, editor. 2008. p. 1-8.
10. Schnell O, Ryden L, Standl E, Ceriello A, Group CES. Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol. 2016;15:139.
11. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429-42.
12. Qaseem A, Barry MJ, Humphrey LL, Forciea MA, Clinical Guidelines Committee of the American College of P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166:279-90.
13. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-200.
14. American Diabetes A. Standards of medical care in diabetes-2017 abridged for primary care providers. Clin Diabetes. 2017;35:5-26.
15. Lehmann R, Bianda T, Brändle M, Czock A, Egli M, Phillippe J, Settler C, Thalmann S, Weng T. Recommandation SSED/SGED: Mesures visant contrôle de la glycémie chez les patients atteints de diabète sucré de type 2. SSED Gdtdl, editor. Switzerland; 2016.
16. Jermendy G, Gaál Z, Gero L, Hidvég IT, Kempler P, Winkler G, Wittmann I. Egészségügyi szakmai irányelv-a diabetes mellitus kórismézésérol, a cukorbetegek antihyperglykaemiás kezelésérol és gondozásáról felnottkorban. Diabetol Hung. 2017;25:3-77.
17. Martinka E, Uličiansky V, Mokáň M, Tkáč I, Galajda P, Schroner Z. Consensual therapeutic algorithm for type 2 diabetes mellitus. Interná Med. 2016;16:301-10.
18. Dedov II, Shestakova MV, Mayorov AY. Standards of specialized diabetes care: 8th edition. Diabetes Mellitus. 2017;20:1-121.
19. ODG. Diabetes mellitus-Anleitungen für die Praxis. Überarbeitete und erweiterte Fassung 2016. Wiener Klinische Wochenschrift. 2016;128:S37-228.
20. Holliday C, Robotin M. The Delphi process: a solution for reviewing novel grant applications. Int J Gen Med. 2010;3:225-30.
21. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526-34.
22. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316:500-8.
23. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22.
24. Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Hantel S, Kempthorne-Rawson J, Newman J, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol. 2014;13:102.
25. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-44.
26. Tahrani AA, Dubb K, Raymond NT, Begum S, Altaf QA, Sadiqi H, Piya MK, Stevens MJ. Cardiac autonomic neuropathy predicts renal function decline in patients with type 2 diabetes: a cohort study. Diabetologia. 2014;57:1249-56.
27. Association TCCotNYH. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little, Brown & Co; 1994. p. 253-6.
28. Wang P, Huang R, Lu S, Xia W, Sun H, Sun J, Cai R, Wang S. HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. Cardiovasc Diabetol. 2015;14:124.
29. Control G, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288-98.
30. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-34.
31. Kaku K, Lee J, Mattheus M, Kaspers S, George J, Woerle HJ, Investigators E-RO. Empagliflozin and cardiovascular outcomes in asian patients with type 2 diabetes and established cardiovascular disease-results from EMPA-REG OUTCOME(R). Circ J. 2017;81:227-34.
32. Mosleh W, Sharma A, Sidhu MS, Page B, Sharma UC, Farkouh ME. The role of SGLT-2 inhibitors as part of optimal medical therapy in improving cardiovascular outcomes in patients with diabetes and coronary artery disease. Cardiovasc Drugs Ther. 2017. doi: 10.1007/s10557-017-6729-y
33. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28.
34. Jardiance PI. Ingelheim B, editor. 2016. p. 1-34.
35. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232-42.
36. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26.
37. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-35.
38. Pfeffer MA, Claggett B, Probstfield JL. Lixisenatide in type 2 diabetes and acute coronary syndrome. N Engl J Med. 2016;374:1095-6.
39. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, Group CPC. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017. 377(7):644-657. doi: 10.1056/NEJMoa1611925
40. Levine MJ. Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials. Curr Diabetes Rev. 2017;13:405-23.
41. Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, Bekiari E, Tsapas A. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984-93.
42. Liakos A, Karagiannis T, Bekiari E, Boura P, Tsapas A. Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015;6:61-7.
43. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-7.
44. Mohammedi K, Potier L, Belhatem N, Matallah N, Hadjadj S, Roussel R, Marre M, Velho G. Lower-extremity amputation as a marker for renal and cardiovascular events and mortality in patients with long standing type 1 diabetes. Cardiovasc Diabetol. 2016;15:5.
45. Paul SK, Klein K, Maggs D, Best JH. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovasc Diabetol. 2015;14:10.
46. Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016;15:37.
47. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jorgensen ME, Thuresson M, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249-59.
48. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3:105-13.
49. Fitchett D. SGLT2 inhibitors in the real world: too good to be true? Lancet Diabetes Endocrinol. 2017;5:673-5.
50. Schernthaner G, Jarvis S, Lotan C, Prazny M, Wanner C, Wascher TC. Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. Ther Clin Risk Manag. 2017;13:69-79.
51. Schernthaner G, Sattar N. Lessons from SAVOR and EXAMINE: some important answers, but many open questions. J Diabetes Complicat. 2014;28:430-3.
52. Ferdinand KC, Botros FT, Atisso CM, Sager PT. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2016;15:38.
53. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008;19:182-7.
54. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, Quartet Study G. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004;89:6068-76.
55. Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir S. Hypoglycaemia with pioglitazone: analysis of data from the prescription-event monitoring study. J Eval Clin Pract. 2010;16:1124-8.